RELATED CONTENT
Breast mammography has become the standard diagnostic breast screening tool in women’s healthcare, aiding in the detection and intervention of early stage breast cancers. Some doctors have reported seeing a 30 percent reduction in breast cancer mortality since the implementation of routine screening mammography.[1] Due to such statistics, women are encouraged to get mammograms annually after the age of 40. However, the benefits of routine mammography have remained a controversial topic within the healthcare community.
June 11, 2013 
According to a new market research report "Breast Imaging Technologies Market (Digital Mammography,3D Breast Tomosynthesis, Breast MRI, Breast Ultrasound, Molecular Breast Imaging, Optical Imaging, PET/CT/PEM Modalities) Technology and Market Analysis & Global Forecasts to 2017" is an attempt to showcase the market impact of current and emerging breast imaging technologies having excellent growth potential in the coming five years. The technologies profiled in the report are segmented into Ionizing breast imaging modalities and Non-Ionizing breast imaging technologies on basis of radiation. Ionizing breast imaging modalities include Mammography, 3D Breast Tomosynthesis, Cone beam Computed Tomography (CBCT), Positron Emission Mammography (PEM), Molecular Breast Imaging (MBI), Positron Emission Tomography (PET) and Breast Specific Gamma Imaging (BSGI). The various Non-ionizing modalities for breast screening covered in the report are Breast MRI, Optical Imaging, Breast thermography and Breast Ultrasound.
January 11, 2013 
GE Healthcare announced it has acquired U-Systems Inc., which recently gained U.S. Food and Drug Administration (FDA) clearance for the somo•v Automated Breast Ultrasound System (ABUS). It is the first ultrasound system on the market for breast cancer screening as an adjunct to mammography for asymptomatic women with greater than 50 percent dense breast tissue and no prior breast interventions. Financial terms were not disclosed.
November 12, 2012 
Over the last few years, new legislation mandating the inclusion of breast density findings in results letters sent to women after their mammography exams has begun appearing in a growing number of states. With three states having already enacted such laws, 17 states working on similar legislation and a federal bill recently introduced in the U.S. House of Representatives, Frost & Sullivan expects widespread breast density reporting laws to have a significant impact on the demand for and utilization of various breast screening technologies.
October 25, 2012 Lately, it seems that breast imagers cannot go a week without reading about new breast imaging research or seeing an article on breast density, the associated risk of breast cancer and the limitations of mammography. In this article, I will summarize today’s current understanding and also provide a look into what I believe the future holds for breast screening.
October 25, 2012 
Lately, it seems that breast imagers cannot go a week without reading about new breast imaging research or seeing an article on breast density, the associated risk of breast cancer and the limitations of mammography. In this article, I will summarize today’s current understanding and also provide a look into what I believe the future holds for breast screening.
October 25, 2012 
September 18, 2012 — The U.S. Food and Drug Administration (FDA) has approved U-Systems' somo•v automated breast ultrasound (ABUS) system for breast cancer screening as an adjunct to mammography for asymptomatic women with dense breast tissue. With the approval, the somo•v ABUS system becomes the only device approved specifically for screening women with dense breasts.
September 18, 2012 
May 14, 2012 — U-Systems, a leader in automated breast ultrasound, announced today it has received a PMA approvable letter from the U.S. Food and Drug Administration (FDA) for the company’s somo•v automated breast ultrasound system (ABUS). The somo•v ABUS system is the first ultrasound device to receive an approval recommendation from an FDA Advisory Panel and an approvable letter for breast cancer screening as an adjunct to mammography for asymptomatic women with dense breast tissue.
May 14, 2012 
April 12, 2012 — U-Systems announced that the U.S. Food and Drug Administration’s (FDA) Radiological Devices Panel of the Medical Devices Advisory Committee recommended approval of the somo•v Automated Breast Ultrasound (ABUS) system.
April 12, 2012 
March 6, 2012 — U-Systems announced the showcase of somo•v Platinum, an update to the somo•v automated breast ultrasound (ABUS) system, at the 2012 National Interdisciplinary Breast Center Conference of the National Consortium of Breast Centers (NCBC).
March 06, 2012